Clinical Trials


The purpose of this section is to serve as an introduction for patients who might be interested in our current trials. Below is a list of the trials we are conducting with links to the pages, where you can find more details about each trial including participating clinical trial sites.

In each section, you will also find information about the various cancer types we are investigating, and details about participating in our trials.

In general, patients obtain access to investigational therapies prior to regulatory approval by participating in clinical trials. There may, however, be circumstances when patients with a serious or life-threatening illness have exhausted all available treatment options and are not eligible to participate in any appropriate clinical trials. In those cases, patients may be eligible for treatment with an investigational therapy through programs referred to as ‘Expanded Access Programs’ (EAPs) or ‘compassionate use’. Click here to read about our policy.

For more details on the technology, development, and product pipeline, please visit the corresponding pages on our site.

For patient inquiries, please contact

Discuss with your doctor whether participating in a clinical trial is right for you.

SPEARHEAD-1 (afamitresgene autoleucel ‘afami-cel’; formerly ADP-A2M4)

This is a Phase 2, open-label, single arm clinical trial to evaluate the anti-tumor activity of afami-cel T-cells in patients who are HLA-A*02 positive and have inoperable locally advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) expressing MAGE-A4. Enrollment for Cohort 1 is now closed, enrolment of Cohort 2 is still open.

View Clinical Trial

SURPASS (uzatresgene autoleucel; 'uza-cel'; formerly ADP-A2M4CD8)

This is a Phase 1, open-label, dose escalation clinical trial to evaluate the safety and anti-tumor activity of next-generation uza-cel T-cells in patients who are HLA-A*02 positive and have inoperable locally advanced urothelial, ovarian, esophageal, esophagogastric junction, gastric, non-small cell lung (NSCLC), or head and neck cancers, expressing MAGE-A4.

View Clinical Trial

SURPASS-3 (uza-cel)

This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of uza-cel as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.

View Clinical Trial